Lv1
38 积分 2021-07-03 加入
Timing and location dictate monocyte fate and their transition to tumor-associated macrophages
17天前
已完结
TGF-β specifies T FH versus T H 17 cell fates in murine CD4 + T cells through c-Maf
19天前
已完结
PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors
1个月前
已完结
Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease
1个月前
已完结
Curing Chronic Hepatitis C — The Arc of a Medical Triumph
1个月前
已完结
A Watershed Moment in the Treatment of Hepatitis C
1个月前
已完结
Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B
1个月前
已完结
GS-010 Outcomes of 48 weeks of therapy and subsequent 24-week post-treatment period with tobevibart (VIR-3434) and elebsiran (VIR-2218) with or without pegylated interferon alfa-2a in chronic hepatitis B virus infection. Findings from the MARCH study
1个月前
已关闭
SOLSTICE: tobevibart plus elebsiran for hepatitis D
1个月前
已完结
Hepatitis D Virus Infection
1个月前
已完结
皖公网安备34019202002308
